About PhagoMed
PhagoMed is a Healthcare company based in Vienna (Austria) founded in 2016 by Jörg schierholz, Burkhard Wippermann, Alexander Belcredi, and Andrej Trampuz, and was acquired by BioNTech in November 2021. Alternatives to antibiotics are developed via phage therapy expertise. PhagoMed has raised $1.7 million across 2 funding rounds from investors including BioNTech. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial.
Company details
PhagoMed is a developing a phage drug development platform through which they are advancing a portfolio of candidates currently at the preclinical stage. The company claims that phage therapy is a better alternative to antibiotics due to the issue of resistance, their insufficient effectiveness against biofilms and also due to their side effects. In exceptional and severe cases the company is exploring experimental treatment options as per the Helsinki protocol for wound and periprosthetic infections. The company is looking for partners to establish preclinical proof of their technology.
- Headquarters Vienna, Austria
- Founders Jörg schierholz, Burkhard Wippermann, Alexander Belcredi, Andrej Trampuz
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website phagomed.com
- Social LinkedIn X
- Acquired by BioNTech (Nov 2021)
Funding Insights of PhagoMed
PhagoMed has successfully raised a total of $1.7M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.7 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.7M
- Total Rounds 2
- Last Round Seed — $1.7M
All 2 funding rounds of PhagoMed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | $1.7M | Seed | – | – | – |
| Jun 2018 | Grant | – | – | – |
1 investors in total: 1 institutional.
Investors in PhagoMed
PhagoMed has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include BioNTech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Immunotherapeutics for cancer and other diseases are developed. | 2008 | biontech.com | Mainz, Germany |
Investor details for PhagoMed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PhagoMed
4 people are tracked at PhagoMed (4 in leadership).
| Name | Role | Group |
|---|---|---|
Jörg schierholz | Co-Founder | Leadership |
Burkhard Wippermann | Co-Founder | Leadership |
Alexander Belcredi | Co-Founder & Managing Director | Leadership |
Andrej Trampuz | Co-Founder | Leadership |
Complete people profiles for PhagoMed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PhagoMed
4 dated milestones of PhagoMed across 5 years, from founding to its latest funding, stage changes and deals.
- Founded PhagoMed is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $1.7M.
- Exit Acquired by BioNTech.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Phagomed
Complete news archive for PhagoMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PhagoMed
PhagoMed was founded in 2016 and raised its 1st funding round 2 years after it was founded.
PhagoMed is headquartered in Vienna, Austria.
PhagoMed is a funded company, having raised a total of $1.7M across 2 funding rounds to date.
PhagoMed is a developing a phage drug development platform through which they are advancing a portfolio of candidates currently at the preclinical stage. The company claims that phage therapy is a better alternative to antibiotics due to the issue of resistance, their insufficient effectiveness against biofilms and also due to their side effects. In exceptional and severe cases the company is exploring experimental treatment options as per the Helsinki protocol for wound and periprosthetic infections. The company is looking for partners to establish preclinical proof of their technology.
PhagoMed has 1 investor. Key investors include BioNTech.
Yes. PhagoMed was acquired by BioNTech in November 2021.